New research presented at the European Respiratory Society (ERS) International Congress being held virtually until September 9, 2020, suggests “social smokers” are more than twice as likely to die of lung disease and over 8-times as likely to die of lung cancer vs non-smokers.
The study, titled “Association of low-intensity smoking with respiratory and lung cancer mortality,” also found that the risk of lung cancer mortality for “social smokers” (those who smoke <10 cigarettes/day) is not substantially lower vs heavy smokers (those who smoke ≥20 cigarettes/day).
The researchers – led by Pallavi Balte, PhD, and Elizabeth Oelsner, MD, MPH, both at Columbia University Medical Center in New York – noted that their study suggests that cutting down, or combining, fewer cigarettes with vaping, is not a substitute for quitting.
“Everyone knows that smoking is bad for you, but it’s easy to assume that if you only smoke a little, the risks won’t be too high,” said Balte to the virtual conference, according to an ERS press release. “Previous research suggests that people are cutting down on smoking, for example in the USA the proportion of smokers smoking less than ten cigarettes per day has increased from 16% to 27%. So, we wanted to study the risks to social smokers compared to people who don’t smoke and compared to heavier smokers.”
The study included 18 730 people selected from a multi-ethnic sample of the general US population; mean age was 61 years old, 56% women, 69% white, 13% current smokers. The median follow-up was 17 years, during which 649 participants died from respiratory causes and 560 died from lung cancer.
Smoking is dangerous, regardless of whether you are a heavy smoker or a social smoker, so if you don’t want to die of lung cancer or respiratory disease, the best action is to quit completely.
Researchers calculated the death rates from respiratory disease and lung cancer and then compared these rates between non-smokers, social smokers, and heavy smokers. Researchers took account of other factors that can influence death rates including age, sex, race, education attainment, and body weight.
The results showed that social smokers were 2.5 times as likely to die of respiratory disease and 8.6 times as likely to die of lung cancer vs non-smokers. Social smokers had around half the rate of death from respiratory diseases as heavy smokers, however, their rate of lung cancer death was two-thirds that of heavy smokers.
“You might think that if you only smoke a few cigarettes a day you are avoiding most of the risk. But our findings [sis] suggesting that social smoking is disproportionately harmful. Smoking is dangerous, regardless of whether you are a heavy smoker or a social smoker, so if you don’t want to die of lung cancer or respiratory disease, the best action is to quit completely,” added Balte.
“Social Smoking” Linked to Disproportionately High Risk of Death from Lung Disease, Lung Cancer
New research presented at the virtual European Respiratory Society International Congress showed "social smokers" are more than twice as likely to die of lung disease vs non-smokers.
New research presented at the European Respiratory Society (ERS) International Congress being held virtually until September 9, 2020, suggests “social smokers” are more than twice as likely to die of lung disease and over 8-times as likely to die of lung cancer vs non-smokers.
The study, titled “Association of low-intensity smoking with respiratory and lung cancer mortality,” also found that the risk of lung cancer mortality for “social smokers” (those who smoke <10 cigarettes/day) is not substantially lower vs heavy smokers (those who smoke ≥20 cigarettes/day).
The researchers – led by Pallavi Balte, PhD, and Elizabeth Oelsner, MD, MPH, both at Columbia University Medical Center in New York – noted that their study suggests that cutting down, or combining, fewer cigarettes with vaping, is not a substitute for quitting.
“Everyone knows that smoking is bad for you, but it’s easy to assume that if you only smoke a little, the risks won’t be too high,” said Balte to the virtual conference, according to an ERS press release. “Previous research suggests that people are cutting down on smoking, for example in the USA the proportion of smokers smoking less than ten cigarettes per day has increased from 16% to 27%. So, we wanted to study the risks to social smokers compared to people who don’t smoke and compared to heavier smokers.”
The study included 18 730 people selected from a multi-ethnic sample of the general US population; mean age was 61 years old, 56% women, 69% white, 13% current smokers. The median follow-up was 17 years, during which 649 participants died from respiratory causes and 560 died from lung cancer.
Researchers calculated the death rates from respiratory disease and lung cancer and then compared these rates between non-smokers, social smokers, and heavy smokers. Researchers took account of other factors that can influence death rates including age, sex, race, education attainment, and body weight.
The results showed that social smokers were 2.5 times as likely to die of respiratory disease and 8.6 times as likely to die of lung cancer vs non-smokers. Social smokers had around half the rate of death from respiratory diseases as heavy smokers, however, their rate of lung cancer death was two-thirds that of heavy smokers.
“You might think that if you only smoke a few cigarettes a day you are avoiding most of the risk. But our findings [sis] suggesting that social smoking is disproportionately harmful. Smoking is dangerous, regardless of whether you are a heavy smoker or a social smoker, so if you don’t want to die of lung cancer or respiratory disease, the best action is to quit completely,” added Balte.
New Research Suggests Cardiac Events are Prevalent in Older Adults Hospitalized with RSV
April 16th 2024Nearly one-quarter of hospitalized adults aged 50 years and older with RSV experienced an acute cardiac event, according to results of a new study.
Respiratory Tripledemic 2022-23: An Expert Recap
April 6th 2023William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Pfizer: MONeT Study Topline Data Positive for Abrysvo in Adults Aged 18 to 59 Years at High Risk for RSV-LRTD
April 9th 2024Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
May 20th 2022In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
Boehringer Ingelheim Will Cap Out of Pocket Costs for Inhalers at $35 per Month
March 7th 2024The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.
CDC: Persons with COVID-19, Flu, RSV, Other Respiratory Viruses No Longer Have to Isolate for 5 Days
March 5th 2024The updated guidelines reflect the progress made in protecting against severe illness from COVID-19, said CDC Director Mandy Cohen, MD, MPH.
New Research Suggests Cardiac Events are Prevalent in Older Adults Hospitalized with RSV
April 16th 2024Nearly one-quarter of hospitalized adults aged 50 years and older with RSV experienced an acute cardiac event, according to results of a new study.
Respiratory Tripledemic 2022-23: An Expert Recap
April 6th 2023William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Pfizer: MONeT Study Topline Data Positive for Abrysvo in Adults Aged 18 to 59 Years at High Risk for RSV-LRTD
April 9th 2024Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
May 20th 2022In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
Boehringer Ingelheim Will Cap Out of Pocket Costs for Inhalers at $35 per Month
March 7th 2024The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.
CDC: Persons with COVID-19, Flu, RSV, Other Respiratory Viruses No Longer Have to Isolate for 5 Days
March 5th 2024The updated guidelines reflect the progress made in protecting against severe illness from COVID-19, said CDC Director Mandy Cohen, MD, MPH.